AE Wealth Management LLC raised its holdings in shares of GSK plc (NYSE:GSK – Get Rating) by 2.4% in the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 100,005 shares of the pharmaceutical company’s stock after acquiring an additional 2,302 shares during the period. AE Wealth Management LLC’s holdings in GSK were worth $3,514,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds also recently made changes to their positions in GSK. Traverso Chambers Private Wealth Management LLC lifted its stake in GSK by 1.8% in the 4th quarter. Traverso Chambers Private Wealth Management LLC now owns 15,913 shares of the pharmaceutical company’s stock valued at $559,000 after purchasing an additional 283 shares during the last quarter. Janiczek Wealth Management LLC raised its holdings in GSK by 49.8% in the 4th quarter. Janiczek Wealth Management LLC now owns 915 shares of the pharmaceutical company’s stock valued at $32,000 after acquiring an additional 304 shares during the period. Arkadios Wealth Advisors lifted its position in GSK by 0.5% during the fourth quarter. Arkadios Wealth Advisors now owns 63,636 shares of the pharmaceutical company’s stock worth $1,554,000 after acquiring an additional 308 shares during the last quarter. Thrive Wealth Management LLC lifted its position in GSK by 3.3% during the fourth quarter. Thrive Wealth Management LLC now owns 10,630 shares of the pharmaceutical company’s stock worth $374,000 after acquiring an additional 336 shares during the last quarter. Finally, Crossmark Global Holdings Inc. lifted its position in GSK by 1.3% during the fourth quarter. Crossmark Global Holdings Inc. now owns 27,537 shares of the pharmaceutical company’s stock worth $967,000 after acquiring an additional 348 shares during the last quarter. Institutional investors own 13.15% of the company’s stock.
Analyst Ratings Changes
Several brokerages have issued reports on GSK. The Goldman Sachs Group began coverage on shares of GSK in a research report on Sunday, February 26th. They set a “buy” rating for the company. Berenberg Bank raised their price objective on shares of GSK from GBX 1,580 ($19.55) to GBX 1,730 ($21.41) in a research report on Friday, February 10th. JPMorgan Chase & Co. raised their price objective on shares of GSK from GBX 1,350 ($16.71) to GBX 1,400 ($17.32) in a research report on Thursday, February 2nd. Deutsche Bank Aktiengesellschaft upgraded shares of GSK from a “hold” rating to a “buy” rating in a research report on Friday, March 17th. Finally, TheStreet upgraded shares of GSK from a “c+” rating to a “b-” rating in a research report on Friday, December 30th. Three analysts have rated the stock with a sell rating, four have assigned a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $1,576.88.
GSK Stock Down 1.6 %
GSK (NYSE:GSK – Get Rating) last announced its quarterly earnings data on Wednesday, February 1st. The pharmaceutical company reported $0.64 EPS for the quarter, beating the consensus estimate of $0.59 by $0.05. GSK had a net margin of 43.75% and a return on equity of 36.37%. The business had revenue of $8.66 billion during the quarter, compared to the consensus estimate of $8.30 billion. Research analysts forecast that GSK plc will post 3.52 EPS for the current fiscal year.
GSK Cuts Dividend
The company also recently disclosed a quarterly dividend, which was paid on Thursday, April 13th. Shareholders of record on Friday, February 24th were given a dividend of $0.3404 per share. The ex-dividend date of this dividend was Thursday, February 23rd. This represents a $1.36 annualized dividend and a yield of 3.70%. GSK’s dividend payout ratio is currently 15.62%.
GSK Company Profile
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the following segments: Commercial Operations, Research and Development, and Consumer Healthcare. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
See Also
- Get a free copy of the StockNews.com research report on GSK (GSK)
- Gamida Cell Stock Jumps Over 100% on FDA Approval
- Insiders Buy EasyJet, Regularly And Repeatedly
- Bank of America Beats Earnings, Renews Investor Upside Potential
- The Analysts See A Bright Future For Sunrun
- J.B. Hunt: Economic Contraction And A Buying Opportunity
Receive News & Ratings for GSK Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GSK and related companies with MarketBeat.com's FREE daily email newsletter.
